Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Idorsia Ltd    IDIA   CH0363463438

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
10/10/2017 10/11/2017 10/12/2017 10/13/2017 10/16/2017 Date
17.75(c) 17.8(c) 17.8(c) 17.8(c) 17.75(c) Last
186 968 191 350 172 857 86 535 90 715 Volume
0.00% +0.28% 0.00% 0.00% -0.28% Change
More quotes
Financials ( CHF)
Sales 2017 96,1 M
EBIT 2017 -183 M
Net income 2017 -232 M
Finance 2017 631 M
Yield 2017 -
Sales 2018 61,4 M
EBIT 2018 -307 M
Net income 2018 -325 M
Finance 2018 379 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 15,5x
EV / Sales2018 28,4x
Capitalization 2 120 M
More Financials
Company
Idorsia Ltd. is a biopharmaceutical company engages in the development of medicines.It specializes in the discovery and development of small molecules used for therapeutic products.It focuses on diseases such as hypertension, systemic lupus erythematosus, chronic insomnia, Aneurysmal subarachnoid... 
Sector
Biotechnology & Medical Research
Calendar

- No events available -

More about the company
Latest news on IDORSIA LTD
05:36p IDORSIA : Invitation to Idorsia's nine-month results 2017 webcast and conference..
08/03 IDORSIA : announces half year results for 2017 - successful start of new biophar..
07/29 IDORSIA : With Positive Phase 2 Results, DORA for Insomnia to Move Into Phase 3 ..
07/28 IDORSIA : ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult a..
06/17 Johnson & Johnson Completes Acquisition of Actelion
More news
Sector news : Bio Therapeutic Drugs
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
10/05DJAppeals Court Rules Against Amgen in Patent Case
09/29 Merck to stop development of hepatitis C treatments
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
More sector news : Bio Therapeutic Drugs
Latest Tweets
05:37pGNW-News: Invitation to Idorsia's nine-month results 2017 webcast and confere.. 
05:36pIdorsia : Invitation to Idorsia's nine-month results 2017 webcast and confere.. 
09/12NKF advises Idorsia on demerger from Actelion and SIX Swiss listing - The Law.. 
08/28The extraordinary adventure of Idorsia, the research-focused biotech, continu.. 
07/29Idorsia touts new sleep drug data ahead of PhIII; Tetraphase out to raise $65.. 
More tweets
Qtime:28
Chart IDORSIA LTD
Duration : Period :
Idorsia Ltd Technical Analysis Chart | IDIA | CH0363463438 | 4-Traders
Technical analysis trends IDORSIA LTD
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 13,4  CHF
Spread / Average Target -25%
EPS Revisions
Managers
NameTitle
Jean-Paul Clozel Chief Executive Officer & Director
Jean-Pierre Garnier Chairman
André C. Muller Chief Financial Officer & Executive Vice President
Martine Clozel Chief Scientific Officer & Executive VP
Robert J. Bertolini Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
IDORSIA LTD0.00%2 175
GILEAD SCIENCES13.35%106 002
REGENERON PHARMACEUTICALS20.67%47 464
VERTEX PHARMACEUTICALS107.56%38 551
ACTELION23.24%29 919
GENMAB22.08%13 910